Kenvue stock (US49177J1025): shares hover below IPO range as investors weigh consumer health outlook

Kenvue shares on the NYSE continue to trade below their 2023 spin-off IPO range, as investors focus on the consumer health group's latest earnings trajectory and valuation metrics relative to staples peers.

Kenvue, the consumer health company spun off from Johnson & Johnson in 2023, remains in focus for U.S. investors as its New York-listed shares trade below their initial IPO range while the market reassesses prospects for branded over-the-counter medicines and personal care products.

According to NYSE data cited by MarketScreener, Kenvue last closed at USD 17.28 on the New York Stock Exchange, with the stock trading under the ticker KVUE and remaining well below the levels seen shortly after its 2023 debut.MarketScreener as of 06/05/2026

The company, headquartered in the United States and listed on the NYSE, became a stand-alone name in consumer health following its separation from Johnson & Johnson, and it now reports as a pure-play in areas such as over-the-counter medicines, skincare and self-care brands that are widely distributed in North America and internationally.

MarketScreener data show that, as of 06/05/2026, analysts' average 12-month price target for Kenvue stands at USD 19.50, indicating that the stock is trading at a discount relative to this consensus view, even as sentiment on U.S. consumer staples remains mixed.MarketScreener as of 06/05/2026

As of: 06/05/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Kenvue
• Sector/industry: Consumer health products
• Headquarters/country: Skillman, United States
• Core markets: North America, Europe and selected international markets
• Key revenue drivers: Over-the-counter medicines, personal care and skincare brands
• Home exchange/listing venue: New York Stock Exchange (KVUE)
• Trading currency: USD

Kenvue: core business model

Kenvue focuses on branded consumer health products, generating revenue primarily through over-the-counter medicines and personal care lines that are distributed through retail and pharmacy channels worldwide.

Valuation metrics and multiples for Kenvue

Investors tracking Kenvue often compare its valuation to a broader set of consumer staples and healthcare peers, using indicators such as price-to-earnings ratios, enterprise-value-based multiples and dividend yields to assess how the stock trades relative to other established brand portfolios.

Based on data compiled by MarketScreener as of 06/05/2026, Kenvue’s share price of USD 17.28 and an average analyst target of USD 19.50 suggest that the market is pricing in moderate growth and resilience from its core consumer health franchises, even as higher interest rates and shifting spending patterns influence valuations across defensive sectors.MarketScreener as of 06/05/2026

Conclusion

Kenvue’s stock on the New York Stock Exchange continues to trade around USD 17.28, below its historical highs and the current average analyst target of USD 19.50, keeping valuation and income characteristics under scrutiny for U.S. investors.

The focus on consumer health brands and over-the-counter products means that Kenvue’s performance is closely watched alongside broader defensive sectors, while valuation multiples help frame how the market balances earnings stability against growth expectations.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.